Current Report Filing (8-k)
22 December 2020 - 7:30AM
Edgar (US Regulatory)
0001460602
false
0001460602
2020-12-16
2020-12-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 16, 2020
ORGENESIS
INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
001-38416
|
|
98-0583166
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation
|
|
File
Number)
|
|
Identification
No.)
|
20271
Goldenrod Lane, Germantown, MD 20876
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (480) 659-6404
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
ORGS
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b -2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers
Compensatory
Arrangements of Certain Officers
Special
remuneration
On
December 16, 2020, the Compensation Committee of the Board of Directors of Orgenesis Inc., a Nevada corporation (the “Company”),
approved a special one-time bonus of $200,000 to Neil Reithinger, the Company’s Chief Financial Officer, Treasurer and Secretary
for his outstanding service to the Company and its affiliates. The payment of such remuneration will be made prior to December
31, 2020.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ORGENESIS
INC.
|
|
|
Date:
December 21, 2020
|
By:
|
/s/
Neil Reithinger
|
|
|
Neil
Reithinger
|
|
|
Chief
Financial Officer, Treasurer and Secretary
|
Innovator Ibd Breakout O... (AMEX:BOUT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Innovator Ibd Breakout O... (AMEX:BOUT)
Historical Stock Chart
From Oct 2023 to Oct 2024